Earnings

Lipocine Q3 EPS $(0.08) Beats $(0.32) Estimate, Sales $2.290M Beat $159.500K Estimate

Nov 5, 2026 · 08:23 AM ET· updated 1h ago

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.32) by 75 percent. This is a 86.44 percent increase over losses of $(0.59) per share from the same

Why It Matters

Lipocine lost less money than experts expected this quarter. When a company loses less than predicted, it shows better control of spending.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

LPCN1.45

+0.01 (+0.69%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.